Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature
- PMID: 29465479
- PMCID: PMC6102096
- DOI: 10.1097/HRP.0000000000000179
Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature
Abstract
Major depressive disorder (MDD) is one of the most prevalent conditions in psychiatry. Patients who do not respond to traditional monoaminergic antidepressant treatments have an especially difficult-to-treat type of MDD termed treatment-resistant depression. Subanesthetic doses of ketamine-a glutamatergic modulator-have shown great promise for rapidly treating patients with the most severe forms of depression. As such, ketamine represents a promising probe for understanding the pathophysiology of depression and treatment response. Through neuroimaging, ketamine's mechanism may be elucidated in humans. Here, we review 47 articles of ketamine's effects as revealed by neuroimaging studies. Some important brain areas emerge, especially the subgenual anterior cingulate cortex. Furthermore, ketamine may decrease the ability to self-monitor, may increase emotional blunting, and may increase activity in reward processing. Further studies are needed, however, to elucidate ketamine's mechanism of antidepressant action.
Similar articles
-
Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression.Int J Neuropsychopharmacol. 2021 May 18;24(5):383-391. doi: 10.1093/ijnp/pyaa089. Int J Neuropsychopharmacol. 2021. PMID: 33249434 Free PMC article. Clinical Trial.
-
Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder.J Affect Disord. 2021 Jan 15;279:239-249. doi: 10.1016/j.jad.2020.10.007. Epub 2020 Oct 7. J Affect Disord. 2021. PMID: 33074143 Free PMC article. Clinical Trial.
-
A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.J Affect Disord. 2014 Mar;156:24-35. doi: 10.1016/j.jad.2013.11.014. Epub 2013 Dec 10. J Affect Disord. 2014. PMID: 24388038 Review.
-
Ketamine: Leading us into the future for development of antidepressants.Behav Brain Res. 2020 Apr 6;383:112532. doi: 10.1016/j.bbr.2020.112532. Epub 2020 Feb 2. Behav Brain Res. 2020. PMID: 32023492 Free PMC article. Review.
-
Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine.Biol Psychiatry Cogn Neurosci Neuroimaging. 2023 Apr;8(4):361-386. doi: 10.1016/j.bpsc.2022.11.005. Epub 2022 Nov 26. Biol Psychiatry Cogn Neurosci Neuroimaging. 2023. PMID: 36775711 Free PMC article. Review.
Cited by
-
The evolutionary old forebrain as site of action to develop new psychotropic drugs.J Psychopharmacol. 2018 Dec;32(12):1277-1285. doi: 10.1177/0269881118798617. Epub 2018 Sep 26. J Psychopharmacol. 2018. PMID: 30255719 Free PMC article. Review.
-
Ketamine's acute effects on negative brain states are mediated through distinct altered states of consciousness in humans.Nat Commun. 2023 Oct 19;14(1):6631. doi: 10.1038/s41467-023-42141-5. Nat Commun. 2023. PMID: 37857620 Free PMC article. Clinical Trial.
-
Neuroimaging correlates and predictors of response to repeated-dose intravenous ketamine in PTSD: preliminary evidence.Neuropsychopharmacology. 2021 Dec;46(13):2266-2277. doi: 10.1038/s41386-021-01104-4. Epub 2021 Jul 31. Neuropsychopharmacology. 2021. PMID: 34333555 Free PMC article. Clinical Trial.
-
Ketamine's rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors.Elife. 2023 Jun 26;12:e86022. doi: 10.7554/eLife.86022. Elife. 2023. PMID: 37358072 Free PMC article.
-
Infusing hope into the treatment of suicidality: A review of ketamine's effects on suicidality.Curr Behav Neurosci Rep. 2019 Dec;6(4):166-176. doi: 10.1007/s40473-019-00184-3. Epub 2019 Dec 2. Curr Behav Neurosci Rep. 2019. PMID: 33457182 Free PMC article.
References
-
- Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatric services. 2014;65:977–87. - PubMed
-
- Kohrs R, Durieux ME. Ketamine: Teaching an old drug new tricks. Anesth Analg. 1998;87:1186–1193. - PubMed
-
- Zarate CA, Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl- D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–864. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials